Navigation Links
HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study
Date:9/24/2009

In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S. Army, the trial sponsor, announced today that the prime-boost investigational vaccine regimen was safe and 31 percent effective in preventing HIV infection.

"These new findings represent an important step forward in HIV vaccine research," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, which provided major funding and other support for the study. "For the first time, an investigational HIV vaccine has demonstrated some ability to prevent HIV infection among vaccinated individuals. Additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection, but certainly this is an encouraging advance for the HIV vaccine field.

"We thank the trial staff in Thailand and the United States for their years of effort in successfully conducting this study and the study participants and the people of Thailand for their long-standing support of HIV vaccine research," Dr. Fauci adds.

The Thai Phase III HIV vaccine study, also known as RV144, opened in October 2003. The placebo-controlled trial tested the safety and effectiveness of a prime-boost regimen of two vaccines: ALVAC-HIV vaccine (the primer dose), a modified canarypox vaccine developed by Sanofi Pasteur, based in Lyon, France, and AIDSVAX B/E vaccine (the booster dose), a glycoprotein 120 vaccine developed by Vaxgen Inc., and now licensed to Global Solutions for Infectious Diseases (GSID), based in South San Francisco, Calif. The vaccines are based on the subtype B and E HIV strains that commonly circulate in Thailand. The subtype B HIV strain is the one most commonl
'/>"/>

Contact: Kathy Stover
stoverk@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research & Road Safety - Queensland (CARRS-Q) study have ... (OSIT) which is being held on the Gold Coast ... road safety researcher, said speed limit credibility was being ... traffic controls remained in place at inactive roadwork sites. ... asked to slow down at roadwork sites but find ...
(Date:9/19/2014)... researchers showed monkeys a number of images representing ... of 39 neurons by using microelectrodes. They found ... intensities of the responses linearly according to either ... This shows that these 3 perceptual parameters are ... variety of glosses. They also found that different ...
(Date:9/19/2014)... The Canton Group, Baltimore’s leading web development firm, has ... Xaverian Brothers. The new site aligns the Catholic order of ... another through a life of Gospel witness lived in community ... care and compassionate love to the people of the world ... responsive web design, which allows users to easily access information ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 Ticket ... Wonder tickets for his 2014 concert tour. Concertgoers ... the music business, there are a handful of artists that ... Wonder. Born in Saginaw, MichIgan, Wonder has been a force ... his time in the music business, he has released 23 ...
(Date:9/19/2014)... September 19, 2014 Lifeinsuranceover50s.biz as released ... who have heart disorders can still qualify for life ... qualify for life insurance plans that do not require ... be purchased online, in just a few minutes. ... also be purchased by clients who have health problems, ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:Neurons express 'gloss' using three perceptual parameters 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... bitten by a bat and subsequently diagnosed with rabies has been ... is being offered, the chances of the boy recovering is very ... of Humble High School fell ill last week, unaware of the ... could happen, a bat had flown into his house while he ...
... study conducted by a team at Queeen's has suggested ... when hooked up to dialysis// yield better results in ... ,This five-month, exercise intervention study of dialysis patients ... King-VanVlack, member of the Cardiac, Circulation and Respiratory (CCR) ...
... that more than 80 million American adults are smokers, obese or ... and an early death. // ,Data from a ... of adults in the United States who have one or both ... categories is about 9 million people and this would include a ...
... study states that the organ donation rate in UK is ... relatives are reluctant to allow such procedures. // This was ... potential organ donors because they are distressed and confused about ... ,The UK Transplant, which carried out a two-year audit, ...
... the Japanese Encephalitis immunization drive has not gone down well ... have taken place on June 18, but the government has ... delivery of 5.2 million doses of the Japanese Encephalitis tissue ... , ,The remaining 13.5 million doses are expected to ...
... to place on record the exemplary work of art by students ... effort by Oman in the ‘Unite for children Unite against Aids’ ... ‘Unite for Children Unite Against Aids’ campaign encompasses four major goals ... the percentage of the young victims of HIV/Aids; to provide better ...
Cached Medicine News:Health News:Exercise Combined with Dialysis Yields Better Results 2Health News:Grieving Relatives Reluctant To Give Consent For Organ Donation 2
(Date:9/19/2014)... 19, 2014 Reductions in kidney ... years in people with diabetes type 2 ... benefits for the kidneys." Australian researchers have ... 2 diabetes leads to persistent reductions in kidney failure ... The global study has found that, five and a ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... , Sept. 18, 2014  Aratana Therapeutics, ... therapeutics company focused on licensing, developing and commercializing ... the full exercise of the underwriters, option to ... connection with the company,s previously announced public offering ... the shares are being offered by Aratana Therapeutics.  ...
Breaking Medicine Technology:ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... Response or Reduction of,Lesion Size by More than ... 2007 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation today announced the ... the safety and,efficacy of pilot process HspE7, an ... women,with the highest grade of cervical dysplasia (CIN ...
... WIRE)--Mar 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israel's ... from trials of BL-1040 demonstrating that,BL-1040 is ... a myocardial infarction (MI), thereby reducing left ... pig model. Professor,Jonathan Leor, MD, Director of ...
Cached Medicine Technology:Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3
Nitinol Flat Wire Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: